Edmonton Symptom Assessment System is a Valid Tool to Measure Symptom Burden Among Decompensated Cirrhosis Patients (GP119)
Journal of Pain and Symptom Management(2024)
摘要
Outcomes
1. Describe the psychometric properties of the revised Edmonton Symptom Assessment System among a longitudinal cohort of ambulatory patients with decompensated cirrhosis.2. Describe the contribution of symptom burden to health-related quality of life among a longitudinal cohort of ambulatory patients with decompensated cirrhosis.
Key Message
The revised Edmonton Symptom Assessment System (ESAS-r) was found to be a reliable and valid tool for longitudinally assessing symptom burden in a prospective cohort of 218 outpatients with decompensated cirrhosis. The ESAS-r can be used in clinical practice and clinical trials as a key outcome measure in cirrhosis care.
Importance
There is a growing need for interventions aimed at addressing physical and psychological symptom burden among patients with decompensated cirrhosis (DC). However, the lack of a validated symptom burden measure in this population is a critical barrier.
Objective(s)
This study investigated the psychometric properties of the revised Edmonton Symptom Assessment System (ESAS-r) in a longitudinal cohort of outpatients with DC.
Scientific Methods Utilized
Adult outpatients with DC were prospectively recruited from a single liver transplant center and completed the ESAS-r at baseline and at week 12. We examined the internal consistency reliability (Cronbach's alpha), structural validity (confirmatory factor analysis), known-groups validity (independent sample t-tests), and floor and ceiling effects. We assessed the convergent validity (Pearson correlations) and predictive validity (regression analysis) of ESAS-r with health-related quality of life (HRQOL) using the Short-Form Liver Disease Quality of Life (SF-LDQOL) questionnaire.
Results
From 7/2018-9/2022, 218 patients with DC (median age 60 years, median MELD-Na 16, 9% Child-Pugh A, 59% Child-Pugh B, 32% Child-Pugh C) completed baseline surveys; 122 completed week 12 surveys. Cronbach's alpha was 0.86, ESAS-r had strong model fit (comparative fit index 0.95), ESAS-r scores significantly increased with increasing disease severity (Child-Pugh A: 25.1 vs. Child-Pugh B: 37.5 vs. Child-Pugh C: 41.4, p=0.006), and there was a floor effect of 9% and ceiling effect of 0.5%. ESAS-r had strong correlation with SF-LDQOL (r= -0.67) and the change in ESAS-r score from baseline to week 12 was a significant predictor of change in SF-LDQOL score (β= -0.36, p< 0.001), accounting for 30% of the change.
Conclusion(s)
The ESAS-r is a reliable and valid tool for longitudinally assessing symptom burden in patients with DC and can predict changes in HRQOL.
Impact
Future directions include implementation of ESAS-r clinical practice and research as a key outcome measure in cirrhosis care.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要